Rifaquizinone (CBR-2092) is a Rifamycin-Quinolone Hybrid Antibiotic . Rifaquizinone inhibits wild-type S. aureus RNA polymerase with an IC 50 of 34 nM. Rifaquizinone is effective against S. aureus infections, with MICs ranged from 0.008 to 0.5 μg/mL for 300 clinical isolates of staphylococci and streptococci .
Products | Products > Disease Areas > Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Infection | Products > Signaling Pathways > Antibiotic | Products > Signaling Pathways > DNA/RNA Synthesis | Products > Signaling Pathways > Bacterial
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.